Correlation between striatal dopamine D2/D3 receptor binding and cardiovascular activity in healthy subjects.
BACKGROUND
The relationship between the striatal dopaminergic system and cardiovascular activity is not well known. The aim of this study is to investigate the relationship between striatal D2/D3 receptor binding and cardiovascular activity.


METHODS
The striatal D2/D3 receptor binding of 34 healthy volunteers was assessed by the single-photon emission computed tomography (SPECT) imaging method with the [123I]-iodobenzoamide (IBZM) ligand. The ratio of the radioactivity in the striatum (St) and the frontal cortex (Fc) (St/Fc ratio) was used as the marker for striatal D2/D3 receptor binding. Their cardiac autonomic functions were measured by continuously monitoring their heart rate and blood pressure (BP) in supine position during 10 min. The heart rate variability (HRV) was analyzed by spectral analysis and the geometric method.


RESULTS
The St/Fc ratio of striatal dopamine D2/D3 receptor binding correlated negatively with heart rate (HR), and positively with cardiac vagal index (CVI) and low frequency (LF) power in healthy subjects who were in a supine resting position.


CONCLUSIONS
Striatal dopamine D2/D3 receptors may play a part in cardiovascular regulation.
Yeh
Tzung-Lieh
TL
Department of Psychiatry, National Cheng Kung University Medical Center, and Department of Neurology, Cheng Ching Hospital, Tainan, Taiwan.
Yang
Yen-Kuang
YK
Chiu
Nan-Tsing
NT
Yao
Wei-Jen
WJ
Yeh
Shoou-Jeng
SJ
Wu
Jin-Shang
JS
Chuang
Jih-Ing
JI
Chang
Shei-Hsi
SH
D000328:Adult; D001341:Autonomic Nervous System / Q000000981:diagnostic imaging / Q000378:metabolism; D001549:Benzamides / Q000008:administration & dosage / Q000378:metabolism; D001794:Blood Pressure; D002148:Calmodulin-Binding Proteins / Q000378:metabolism; D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000000981:diagnostic imaging / Q000378:metabolism*; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000378:metabolism; D005260:Female; D005625:Frontal Lobe / Q000000981:diagnostic imaging / Q000378:metabolism; D006339:Heart Rate; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000378:metabolism; D011237:Predictive Value of Tests; D011485:Protein Binding; D011759:Pyrrolidines / Q000008:administration & dosage / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3 / Q000378:metabolism; D012016:Reference Values; D016683:Supine Position; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D002148:Calmodulin-Binding Proteins; D018492:Dopamine Antagonists; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C491925:STRN protein, human; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide